<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670069</url>
  </required_header>
  <id_info>
    <org_study_id>RG9218021</org_study_id>
    <secondary_id>NCI-2018-00615</secondary_id>
    <secondary_id>9715</secondary_id>
    <secondary_id>5P30CA015704</secondary_id>
    <nct_id>NCT03670069</nct_id>
  </id_info>
  <brief_title>Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas</brief_title>
  <official_title>A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune Microenvironment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas&#xD;
      that do not respond to treatment (refractory) and have spread to other parts of the body&#xD;
      (advanced/metastatic). Itacitinib may cause changes in the immune system and the body's&#xD;
      immune response to cancer, which may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Patients receive itacitinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 7 and 30 days, every 12&#xD;
      weeks from baseline for up to 1 year, and then every 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the percentage of cells which are immune inhibitory (CD11B+, CD163+) macrophages from pre-treatment to first post-treatment biopsy</measure>
    <time_frame>From baseline to 2 years</time_frame>
    <description>Evaluation of the change in percentages of cells against the null hypothesis of no difference will be performed using a 1-sided t-test at the 0.05 level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be graded according to Common Terminology Criteria for Adverse Events version 5.0. The frequency and severity of toxicities will be evaluated by proportions and associated 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>At 6 months</time_frame>
    <description>Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Distributions and percentages at landmark times for time to event outcomes will be estimated using the method of Kaplan-Meier. Confidence intervals about medians will be estimated using the method of Brookmeyer-Crowley. With 12 LMS patients, binary proportions can be estimated to within 29% with 95% confidence. With 8 (SS or MRCL) and PUS, respectively, binary proportions can be estimated to within 36% with 95% confidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>At 12 months</time_frame>
    <description>Distributions and percentages at landmark times for time to event outcomes will be estimated using the method of Kaplan-Meier. Confidence intervals about medians will be estimated using the method of Brookmeyer-Crowley. With 12 LMS patients, binary proportions can be estimated to within 29% with 95% confidence. With 8 (SS or MRCL) and PUS, respectively, binary proportions can be estimated to within 36% with 95% confidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (complete response [CR]+ partial response [PR]+stable disease [SD])</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>CR and PR will be defined as per RECIST 1.1 Distributions and percentages at landmark times for time to event outcomes will be estimated using the method of Kaplan-Meier. Confidence intervals about medians will be estimated using the method of Brookmeyer-Crowley. With 12 LMS patients, binary proportions can be estimated to within 29% with 95% confidence. With 8 (SS or MRCL) and PUS, respectively, binary proportions can be estimated to within 36% with 95% confidence.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Metastatic Leiomyosarcoma</condition>
  <condition>Metastatic Synovial Sarcoma</condition>
  <condition>Metastatic Undifferentiated Pleomorphic Sarcoma</condition>
  <condition>Advanced Myxoid Liposarcoma</condition>
  <condition>Advanced Soft Tissue Sarcoma</condition>
  <condition>Metastatic Myxoid Liposarcoma</condition>
  <condition>Metastatic Round Cell Liposarcoma</condition>
  <condition>Metastatic Soft Tissue Sarcoma</condition>
  <condition>Refractory Leiomyosarcoma</condition>
  <condition>Refractory Myxoid Liposarcoma</condition>
  <condition>Refractory Round Cell Liposarcoma</condition>
  <condition>Refractory Soft Tissue Sarcoma</condition>
  <condition>Refractory Synovial Sarcoma</condition>
  <condition>Refractory Undifferentiated Pleomorphic Sarcoma</condition>
  <condition>Advanced Leiomyosarcoma</condition>
  <condition>Advanced Synovial Sarcoma</condition>
  <condition>Advanced Undifferentiated Pleomorphic Sarcoma</condition>
  <condition>Metastatic Chondrosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (itacitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive itacitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (itacitinib)</arm_group_label>
    <other_name>1334298-90-6</other_name>
    <other_name>3-Azetidineacetonitrile</other_name>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (itacitinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have a histologically confirmed diagnosis of sarcoma with one of the following&#xD;
             subtypes:&#xD;
&#xD;
               -  Cohort 1: Leiomyosarcoma&#xD;
&#xD;
               -  Cohort 2: Undifferentiated pleiomorphic sarcoma&#xD;
&#xD;
               -  Cohort 3: Synovial sarcoma or myxoid/round cell liposarcoma&#xD;
&#xD;
               -  Cohort 4: Chondrosarcoma (all subtypes of chondrosarcoma are allowed)&#xD;
&#xD;
          -  Subjects must have received at least two prior lines of systemic therapy&#xD;
&#xD;
          -  All ongoing toxicities related to prior therapies must be resolved to grade 1 or&#xD;
             better (except alopecia)&#xD;
&#xD;
          -  Subjects must have one or more measurable lesions, as determined by Response&#xD;
             Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 assessed by computed&#xD;
             tomography (CT) or magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  Subjects must have at least one superficial lesion accessible for multiple biopsies;&#xD;
             the tumor being biopsied cannot have been previously targeted for radiation therapy or&#xD;
             have previously received intra-lesional treatment&#xD;
&#xD;
             * NOTE: Superficial lesions previously targeted with radiation therapy that have&#xD;
             demonstrated significant new growth via radiological imaging may be targeted for&#xD;
             biopsy, with sponsor-investigator approval.&#xD;
&#xD;
          -  Total bilirubin level =&lt; 1.5 x the upper limit of normal (ULN) range mg/dL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) =&lt; 2.5 x ULN and alanine aminotransferase (ALT)&#xD;
             levels =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 x ULN&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Calculated creatinine clearance &gt;= 30 mL/min using the Cockcroft-Gault formula may be&#xD;
             included&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 Ã— 10^9/L&#xD;
&#xD;
          -  Platelet count &gt;= 100 x 10^9/L; transfusion is permitted as clinically indicated&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
             * Transfusion is permitted as clinically indicated&#xD;
&#xD;
          -  Subjects must have a life expectancy &gt;= 6 months, as determined by the treating&#xD;
             physician&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 or Karnofksy&#xD;
             performance status &gt;= 60&#xD;
&#xD;
          -  Male or non-pregnant and non-breast feeding female:&#xD;
&#xD;
               -  Females of child-bearing potential must agree to use highly effective&#xD;
                  contraception without interruption from initiation of therapy and while on study&#xD;
                  medication and have a negative serum pregnancy test (beta - human chorionic&#xD;
                  gonadotropin [hCG]) result at screening and agree to ongoing pregnancy testing&#xD;
                  during the course of the study, and at the end of study treatment; a highly&#xD;
                  effective method of contraception is defined as one that results in a low failure&#xD;
                  rate (that is, &lt; 1% per year), when used consistently and correctly, such as&#xD;
                  implants, injectables, combined oral contraceptives, some intrauterine&#xD;
                  contraceptive devices, sexual abstinence, or a vasectomized partner&#xD;
&#xD;
               -  Male subjects must practice abstinence or agree to use a condom during sexual&#xD;
                  contact with a pregnant female or a female of childbearing potential while&#xD;
                  participating in the study&#xD;
&#xD;
          -  Ability to understand and sign informed consent document&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, laboratory tests, and other&#xD;
             study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known active, uncontrolled, or symptomatic central nervous system (CNS) metastases; a&#xD;
             subject with controlled and asymptomatic CNS metastases may participate in this study;&#xD;
             as such, the subject must have completed any prior treatment for CNS metastases &gt;= 28&#xD;
             days (including radiotherapy and/or surgery) prior to the start of treatment in this&#xD;
             study and should not be receiving chronic corticosteroid therapy for CNS metastases;&#xD;
             subjects with known CNS metastases must be confirmed radiographically stable by at&#xD;
             least one imaging study, at least 28 days from last treatment&#xD;
&#xD;
          -  Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy&#xD;
             (including investigational) within 2 weeks of enrollment&#xD;
&#xD;
          -  Prior treatment with a drug targeting JAK1, JAK1/2 or STAT3 inhibitor; Food and Drug&#xD;
             Administration (FDA) approved small molecule tyrosine kinase inhibitors (TKIs) not&#xD;
             specifically designed to target this pathway are okay (e.g. pazopanib, sunitinib,&#xD;
             sorafenib)&#xD;
&#xD;
          -  Known, active drug or alcohol abuse&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Active or recent infection requiring systemic anti-infective treatment that was&#xD;
             completed =&lt;14 days prior to enrollment (with the exception of uncomplicated urinary&#xD;
             tract infection or upper respiratory infection)&#xD;
&#xD;
          -  Uncontrolled or concurrent illness including, but not limited to, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Oral steroid usage within =&lt; 14 days prior to enrollment&#xD;
&#xD;
          -  Known inflammatory or autoimmune disease which requires patient to occasionally&#xD;
             require high dose oral steroids&#xD;
&#xD;
          -  Subjects with known, active human immunodeficiency virus (HIV) infection (subjects&#xD;
             with undetectable viral load and normal CD4+ 1-cell count are permitted)&#xD;
&#xD;
          -  Inability to swallow food or tablets, or significant gastrointestinal disorder that,&#xD;
             in the opinion of the investigator, could interfere with absorption of the study drug&#xD;
&#xD;
          -  Previous reaction to any component of itacitinib or known hypersensitivity to the&#xD;
             active substance or any of the excipients&#xD;
&#xD;
          -  Subjects with a sarcoma which has other, defined treatments or biology distinctly&#xD;
             different from those of soft tissue sarcomas in general; including, but not limited&#xD;
             to, Ewing's sarcoma, rhabdomyosarcoma, gastrointestinal stromal tumors, Kaposi's&#xD;
             sarcoma, Wilm's tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wagner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roxanne Moore</last_name>
    <phone>206-606-6425</phone>
    <email>romoore@seattlecca.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Moore</last_name>
      <phone>206-606-6425</phone>
      <email>romoore@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Michael Wagner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

